Context: Atypical antipsychotics (SGA) have the propensity to induce weight gain. Objective: The aim was to evaluateearly changes in hormones involved in neuroendocrine regulations (serum cortisol, growth hormone and prolactin) and positive energy balance (serum insulin, leptin and ghrelin) during SGA treatment in normal-weight patients with schizophrenia with the purpose of exploring the possibility to combat weight gain early through manipulation of circulating hormone levels. Design: We conducted a randomized, partly cross-sectional and partly longitudinal, prospective study. Setting and Patients: Eighteen normal-weight in-patients with schizophrenia treated with FGA (first-generation antipsychotics) were referred to the Institute of Psychiatry. Twenty age-, gender- and BMI-matched healthy subjects were investigated at the Neuroendocrine Unit, Belgrade University. Intervention: Oral glucose tolerance test (OGTT) was performed at baseline in all and then 13 patients were assigned to receive SGA (risperidone or clozapine) and OGTT was repeated after 1 and 3 months. Results: At baseline, patients with schizophrenia had higher peak glucose levels (p < 0.05), glucose area under the curve (AUC; p < 0.05), peak insulin levels (p < 0.05), insulin AUC values during OGTT (p < 0.01) and the calculated homeostasis model assessment (HOMA-IR) value than control subjects (p < 0.05). Patients with schizophrenia showed higher morning cortisol (p < 0.05) levels than control subjects. After 1 and 3 months of SGA therapy patients with schizophrenia gained bodyweight by 3.5 and 8.6%, respectively. Leptin levels steadily increased while cortisol levels decreased in the first month and remained so. Serum glucose, insulin and ghrelin levels on SGA were similar as at baseline. Circulating ghrelin levels decreased after OGTT during SGA which is consistent with a role for ghrelin in the initiation of meals. Conclusions: Treatment with SGA was associated with continuous weight gain, with an early increase in serum leptin levels and decrease in cortisol levels. Elevated circulating leptin was ineffective in the control of fat deposition. Similar plasma ghrelin levels and similar decrease pattern of ghrelin after OGTT compared to healthy subjects signify intact meal-promoting effects of ghrelin during SGA therapy, which at the same time renders anorexigenic pathways ineffective. This may lead to weight gain and further studies with a ghrelin antagonist may provide support for this hypothesis.

Keywords:
Antipsychotics, Weight gain, Insulin, Ghrelin, Growth hormone, Leptin, Cortisol
1.
Casey D, Haupt D, Newcomer J, Henderson D, Sernyak M, Davidson M, Lindenmayer JP, Manoukian S, Banjeri M, Lebovitz H, Hennekens C: Anti-psychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65:4–18.
2.
Tarricone I, Casoria M, Ferrari B: Metabolic risk factor profile associated with use of second generation antipsychotics: a cross-sectional study in a community mental health centre. BMC Psychiatry 2006;6:1–8.
3.
Wehmeier PM, Gebhardt S, Schmidtke J, Remschmidt H, Hebebrand J, Theisen FM: Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 2005;133:273–276.
4.
Cowley M: Hypothalamic melanocortin neurons integrate signals of energy state Euro J Pharmacol 2003;480:3–11.
5.
Coll A, Challis B, Yeo G, Farooqi I, O’Rahilly S: Melanocortin receptors and energy homeostasis. Curr Opin Endocrinol Diab 2005;12:205–210.
6.
Horvath T: Synaptic plasticity in energy balance regulation. Obesity 2006;14:228S–233S.
7.
Kay S, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
8.
Mathews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412–419.
9.
Zigman J, Elmquist J: Minireview: From anorexia to obesity – the yin and yang of body weight control. Endocrinology 2003;144:3749–3756.
10.
Considine R, Sinha M, Heiman M, Kriauciunas A, Stephens T, Nyce M, Ohannesian J, Marco C, McKee L, Bauer T, Caro J: Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292–295.
11.
Caro J, Kolaczynski J, Nyce M, Okannesian J, Opentanova I, Goldman W, Lynn R, Zhang P, Sinha M, Considine R: Decreased cerebrospinal-fluid serum/leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996;348:159–161.
12.
Sahu A: Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 2004;24:225–253.
13.
Licinio J, Mantzoros C, Negrao A, Cizza G, Wong M, Bongiorno P, Chrousos G, Karp B, Allen C, Flier J, Gold P: Human leptin: levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997;3:575–579.
14.
Ravussin E, Tschop M, Morales S, Bouchard C, Heiman M: Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins. J Clin Endocrinol Metab 2001;86:4547–4551.
15.
Haqq A, Farooqi S, O’Rahilly S, Stadler D, Rosenfeld R, Pratt K, LaFranchi S, Purnell J: Serum ghrelin levels are inversely correlated with body mass index, age and insulin concentrations in normal children and are markedly increased in Prader-Willi. J Clin Endocrinol Metab 2003;88:174–178.
16.
Himmerich H, Fulda S, Kunzel H, Pfennig A, Dzaja A, Cummings D, Pollmacher T: Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 2005;52:11–16.
17.
Van der Lely AJ, Tschop M, Heiman M, Ghigo E: Biological physiological, pathophysiological and pharmacological aspects of ghrelin. Endocr Rev 2004;25:426–457.
18.
Flanagan D, Evans M, Monsod T, Rife F, Heptulla R, Tamborlane W, Sherwin R: The influence of insulin on circulating ghrelin. Am J Physiol 2003;284:E313–E316.
19.
Theisen FM, Gebhardt S, Bromel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M, Krieg JC, Remschmidt H, Tschop M, Hebebrand J: A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005;112:1411–1416.
20.
Palik E, Birkas KD, Faludi G, Karadi I, Cseh K: 2005 Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diab Res Clin Pract 2005;68:S60–S64.
21.
Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal M, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S: Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002;87:240–244.
22.
Nakagawa E, Nagaya N, Okamura H, Enomoto M, Oya H, Ono F, Hosoda H, Kojima M, Kangawa K: Hyperglycemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide responses to the intravenous and oral administration of glucose. Clin Sci (Lond) 2002;103:325–328.
23.
Cummings DE: Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006;89:71–84.
24.
Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y: Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. Psychopharmacology 2006;20:75–79.
25.
Theisen FM, Gebhardt S, Bromel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M, Krieg JC, Remschmidt H, Tschop M, Hebebrand J: A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005;112:1411–1416.
26.
Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, Deysher AE, Waxman AR, White RD, Williams TD, Lachey JL, Seeley RJ, Lowell BB, Elmquist JK: Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005;115:3564–3572.
27.
Luque R, Kineman R: Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology 2006;147:2754–2763.
28.
Sernyak M, Leslie D, Alarcon R: Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561–566.
29.
Newcomer J, Haupt D, Fucetola R: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337–345.
30.
Ryan M, Collins P, Thakore J: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284–289.
31.
Zhang Z, Yao Z, Liu W, Fang Q, Reynolds G: Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry 2004;184:58–62.
32.
Ader M, Kim S, Hucking K, Kabir M, Bergman RN: Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. Diabetes 2005;54:862–871.
33.
Best L, Yates A, Reynolds G: Actions of antipsychotic drugs on pancreatic beta-cell function: contrasting effects of clozapine and haloperidol. Psychopharmacology 2005;19:596–601.
34.
Sowell M, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S, Ray A, Davis T, Breier A, Henry R, Dananberg J: Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone or placebo: a prospective, randomized study using the two-step hyperglycaemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875–5880.
35.
Tandon R, Halbreich U: The second generation ‘atypical’ antipsychotics: similar improved efficacy but different neuroend crineside effects. Psychoneuroendocrinology 2003;28:1–7.
36.
Peters A, Schweiger U, Pellerin L, Hubold C, Oltmanns KM, Conrad M, Schultes B, Born J, Fehm HL: The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004;28:143–180.
37.
Peters A, Pellerin L, Dallman M, Oltmans K, Schmiger U, Born J, Fehm J: Causes of obesity: looking beyond the hypothalamus. Prog Neurobiol 2007;81:61–88.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.